Gastroenterology

California's Governor Signs Bill for State to Produce Its Own Biosimilars, Insulins

September 29th 2020

By Skylar Jeremias

California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.

Alexion's Ultomiris Gains aHUS Indication in Japan

September 26th 2020

By Tony Hagen

Article

An advance is notched for the ravulizumab (Ultomiris) follow-on product from Alexion. Clinical findings in atypical hemolytic uremic syndrome (aHUS) are provided.

Stakeholders Joust Over Biosimilar Availability at PCOC20

September 25th 2020

By Tony Hagen

Article

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Alexion Gets CHMP Nod for New Ultomiris Formulation

September 22nd 2020

By Skylar Jeremias

Article

The Committee for Medicinal Products for Human Use (CHMP) recommendation for ravulizumab (Ultomiris) is for a dosage that involves a less rigorous schedule for administration.

Lotus Inks Deal With CKD to Distribute Darbepoetin Alpha Biosimilar

September 21st 2020

By Tony Hagen

Article

Lotus and CKD Pharmaceutical intend to be among the first to bring a darbepoetin alpha biosimilar to Southeast Asia.

Celltrion, Intract Pharma Strive for World's First Oral Infliximab

August 22nd 2020

By Tony Hagen

Article

Intract Pharma believes infliximab can be delivered orally and, in conjunction with Celltrion Group, aims to apply its technology and expertise to make it happen.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 16th 2020

By Tony Hagen

Article

An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.

In Search of Better Algorithms for Treatment of Crohn Disease

July 16th 2020

By Deana Ferreri, PhD

Article

Wide variation in treatment patterns for Crohn disease is attributable to failures to translate evidence uniformly and cost barriers. Authors of a new report have formulated algorithms to help reduce heterogeneity in treatment of patients.

Use of Infliximab Biosimilar in Medicare Population Is Low but Growing

July 7th 2020

By Deana Ferreri, PhD

Article

Slow growth of use of biosimilar infliximab in a Medicare fee-for-service population suggests lingering hesitancy on the part of gastroenterologists and patients, particularly when it comes to extrapolation to off-label uses, according to a new study.

Looking Back, UK Patients Unhappy With Adalimumab Biosimilar Switch

June 24th 2020

By Allison Inserro

Article

The UK results show how challenging switching to a biosimilar can be, according to patient groups.